Literature DB >> 12758192

Can we control tuberculosis in high HIV prevalence settings?

Peter Godfrey-Faussett1, Helen Ayles.   

Abstract

The overlap between the epidemiology of HIV and tuberculosis and consequent rapid rise in numbers of patients with tuberculosis in many African countries has put a huge burden on health systems. The stigma of HIV has increased the existing stigma surrounding tuberculosis. There are three mechanisms by which we may reduce the number of cases of tuberculosis in a community: reducing transmission of tuberculosis, reducing reactivation of latent tuberculosis infection and reducing HIV transmission. Reinforcing the existing health service to find more cases, active case-finding in communities or enhanced case-finding in specific groups will reduce transmission of tuberculosis. However, health services that find it difficult to find cases efficiently will also find it difficult to support patients throughout treatment to achieve a cure. Partnership with traditional healers, community-based organizations and private practitioners could reduce this burden. Reactivation of tuberculosis among people living with HIV can be reduced by tuberculosis preventive therapy or by antiretroviral therapy. Programmes that identify people living with HIV can also implement enhanced tuberculosis case-finding increasing the benefits of the programme. However, the impact of widespread use of antiretroviral therapy may be to increase the number of people in a community who are mildly immunocompromised and the incidence of tuberculosis at a community level might rise. Any strategy that successfully reduces HIV transmission will benefit tuberculosis control, since around a third of all HIV-positive individuals will develop tuberculosis before they die. To control tuberculosis in high HIV prevalence settings, we must strengthen health systems to include not only expansion of the DOTS strategy but also full-blooded implementation of voluntary counselling and testing, enhanced and active tuberculosis case-finding, preventive therapy and better care for people living with HIV including antiretroviral therapy. The approach needed to control tuberculosis needs also to be integrated into broader development and poverty reduction goals.

Entities:  

Mesh:

Year:  2003        PMID: 12758192     DOI: 10.1016/s1472-9792(02)00083-5

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  21 in total

1.  Care seeking and attitudes towards treatment compliance by newly enrolled tuberculosis patients in the district treatment programme in rural western Kenya: a qualitative study.

Authors:  John G Ayisi; Anna H van't Hoog; Janet A Agaya; Walter Mchembere; Peter O Nyamthimba; Odylia Muhenje; Barbara J Marston
Journal:  BMC Public Health       Date:  2011-06-29       Impact factor: 3.295

Review 2.  Tuberculosis and stigmatization: pathways and interventions.

Authors:  Andrew Courtwright; Abigail Norris Turner
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

3.  Clinical relevance of Mycobacterium tuberculosis plcD gene mutations.

Authors:  Zhenhua Yang; Dong Yang; Ying Kong; Lixin Zhang; Carl F Marrs; Betsy Foxman; Joseph H Bates; Frank Wilson; M Donald Cave
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

4.  Clinical latency and reactivation of AIDS-related mycobacterial infections.

Authors:  Yun Shen; Ling Shen; Prabhat Sehgal; Dan Huang; Liyou Qiu; George Du; Norman L Letvin; Zheng W Chen
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.

Authors:  Krishna P Reddy; Mark F Brady; Robert H Gilman; Jorge Coronel; Marcos Navincopa; Eduardo Ticona; Gonzalo Chavez; Eduardo Sánchez; Christian Rojas; Lely Solari; Jorge Valencia; Yvett Pinedo; Carlos Benites; Jon S Friedland; David A J Moore
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

6.  Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury.

Authors:  V L D Bonato; E D C Gonçalves; E G Soares; R R Santos Júnior; A Sartori; A A M Coelho-Castelo; C L Silva
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

7.  Missed opportunities for diagnosis of tuberculosis and human immunodeficiency virus co-infection in Moshi, Tanzania.

Authors:  A C Tribble; C D Hamilton; J A Crump; A Mgonja; A Mtalo; E Ndanu; D K Itemba; K Z Landman; M Shorter; E M Ndosi; J F Shao; J A Bartlett; N M Thielman
Journal:  Int J Tuberc Lung Dis       Date:  2009-10       Impact factor: 2.373

8.  Socio-demographic and AIDS-related factors associated with tuberculosis stigma in southern Thailand: a quantitative, cross-sectional study of stigma among patients with TB and healthy community members.

Authors:  Aaron M Kipp; Petchawan Pungrassami; Kittikorn Nilmanat; Sohini Sengupta; Charles Poole; Ronald P Strauss; Virasakdi Chongsuvivatwong; Annelies Van Rie
Journal:  BMC Public Health       Date:  2011-08-30       Impact factor: 3.295

9.  ZAMSTAR, The Zambia South Africa TB and HIV Reduction Study: design of a 2 x 2 factorial community randomized trial.

Authors:  Helen M Ayles; Charalambos Sismanidis; Nulda Beyers; Richard J Hayes; Peter Godfrey-Faussett
Journal:  Trials       Date:  2008-11-07       Impact factor: 2.279

10.  Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV.

Authors:  Helen Ayles; Albertus Schaap; Amos Nota; Charalambos Sismanidis; Ruth Tembwe; Petra De Haas; Monde Muyoyeta; Nulda Beyers
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.